Katrina Pack, MD
Neuromuscular Medicine · Lafayette, CONPI 1144517947
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,071 of the $2,521 with a category attached, or 82.2%. It is spread thinly across 26 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $854 and has fallen 80.6% since, to $166 in 2025.
Across 107 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$506
- Amgen$377
- Novartis$270
- EMD Serono, Inc.$204
- AbbVie$182
- Biohaven Pharmaceuticals, Inc.$175
- plus $807 from 20 others
What the payments were for
- Consulting fees$45018%
- Food & beverage$2,07182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 7 | $506 |
| Amgen | 12 | $377 |
| Novartis | 17 | $270 |
| EMD Serono, Inc. | 7 | $204 |
| AbbVie(2 entities) | 12 | $182 |
| Biohaven Pharmaceuticals, Inc. | 10 | $175 |
| Pfizer | 7 | $135 |
| UCB, Inc. | 4 | $91 |
| Abbott | 4 | $87 |
| Neurocrine Biosciences, Inc. | 4 | $76 |
| Mallinckrodt Enterprises LLC | 2 | $55 |
| Argenx US, Inc. | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Boston Scientific | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Medtronic | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$450
- AIMOVIG$230
- NURTEC ODT$125
- Mavenclad$108
How this compares
Too few neuromuscular medicine providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $373,077 |
| AustedoDeutetrabenazine | 14 | $200,752 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 20 | $160,169 |
| Kesimpta PenOfatumumab | 13 | $131,125 |
| BriviactBrivaracetam | 24 | $33,026 |
| LamictalLamotrigine | 21 | $23,920 |
| QuliptaAtogepant | 22 | $23,112 |
| Emgality PenGalcanezumab-Gnlm | 19 | $19,069 |
| Glatiramer Acetate | 13 | $13,927 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,818 |
| Levetiracetam | 138 | $4,874 |
| Carbamazepine ErCarbamazepine | 31 | $4,137 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 154 | $3,921 |
| Rasagiline Mesylate | 25 | $3,311 |
| Rivastigmine | 17 | $2,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $18 | $200,75214 claims |
| UCB, Inc.Briviact | $91 | $33,02624 claims |
| AbbVieQulipta | $182 | $23,11222 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $28 | $2,84942 claims |
| Upsher-smith Laboratories LLCTopiramate | $13 | $80672 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Lafayette
- Stacy DixonAurora$44K
- Alexander DietzEnglewood$15K
- Dianna QuanAurora$9K
- Monika Krzesniak SwinarskaAurora$1K
- Vera FridmanAurora$534
- Brian McIntyreDenver$166
- Grace VeneziaAurora$138
- Maryam Tahmasbi SohiAurora$54
- Jessica KelnerDenver$21
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.